Last reviewed · How we verify
Laboratorios Osorio de Moraes Ltda. — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
3 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Pílulas de Lussen | Pílulas de Lussen | phase 3 | ||||
| Auris-Sedina | Auris-Sedina | phase 3 | Benzodiazepine | GABA_A receptor | Neurology | |
| Otosynalar® | Otosynalar® | phase 3 | Topical corticosteroid-antibiotic combination | Otolaryngology / Dermatology |
Therapeutic area mix
- Neurology · 1
- Otolaryngology / Dermatology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Ajenat Pharms · 1 shared drug class
- Assaf-Harofeh Medical Center · 1 shared drug class
- Azienda Ospedaliera Universitaria Policlinico "G. Martino" · 1 shared drug class
- B.P. Koirala Institute of Health Sciences · 1 shared drug class
- Bausch Health · 1 shared drug class
- Centro Medico Nacional La Raza, IMSS · 1 shared drug class
- Chang Gung Memorial Hospital · 1 shared drug class
- · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Laboratorios Osorio de Moraes Ltda.:
- Laboratorios Osorio de Moraes Ltda. pipeline updates — RSS
- Laboratorios Osorio de Moraes Ltda. pipeline updates — Atom
- Laboratorios Osorio de Moraes Ltda. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Laboratorios Osorio de Moraes Ltda. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/laboratorios-osorio-de-moraes-ltda. Accessed 2026-05-16.